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ABSTRACT
In total, 172 isolates of Enterobacteriaceae, Acine-
tobacter spp., Pseudomonas aeruginosa and Stenotro-
phomonas maltophilia were tested for susceptibility
to colistin by agar dilution, Etest and the Vitek 2
system. Isolates with a colistin MIC £2 mg ⁄L were
considered to be susceptible. Fifty-four (31%)
Gram-negative isolates were resistant to colistin.
Categorical agreement between agar dilution and
Etest was 87%, and between agar dilution and
Vitek 2 was 82%. Based on the data obtained, the
Vitek 2 system was unreliable for detecting colis-
tin resistance, and results obtained by Etest may
require confirmation by a standard MIC suscep-
tibility testing method.
Keywords Agar dilution, colistin, Etest, resistance,
susceptibility testing, Vitek 2
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Increasing antibiotic resistance in Gram-negative
bacilli, coupled with a shortage of new anti-
microbial agents, has led to renewed interest in
the use of polymyxins for treating multidrug-
resistant infections [1]. There are few guidelines
for antibiotic susceptibility testing of polymyxins.
The CLSI issued interpretative breakpoints for
Acinetobacter spp. only in 2005 [2], and disk
susceptibility testing generally yields poor results
with colistin [3]. Determination of colistin MICs is
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considered to be the optimum method, but is
impractical for most clinical microbiology labor-
atories. Alternative methods include the Etest
(AB Biodisk, Solna, Sweden) and automated
susceptibility testing systems, e.g., the Vitek 2
system (bioMe´rieux, Marcy l’Etoile, France). This
study compared these three methods for testing
colistin susceptibility.
In total, 172 non-duplicate isolates of Entero-
bacteriaceae, Acinetobacter spp., Pseudomonas
aeruginosa and Stenotrophomonas maltophilia were
collected from clinical specimens over a 24-month
period. Bacterial suspensions were prepared from
overnight cultures using a nephelometer
(bioMe´rieux) to give an initial density of
0.5 · McFarland standard for Etest and agar
dilution, and 0.6 · McFarland standard for
Vitek 2, followed by a dilution step to yield a test
inoculum of 104 CFU for agar dilution.
MICs of colistin were determined by agar
dilution [4], in which colistin sulphate powder
(Sigma-Aldrich, Singapore) in solution was
added to molten Mueller–Hinton agar (Becton-
Dickinson, Franklin Lakes, MD, USA) to provide
two-fold dilutions ranging from 0.25 to
128 mg ⁄L. Bacterial suspensions were applied
to agar plates using a multipoint inoculator
(Mast Diagnostics, Bootle, UK). Results were
read following incubation at 35C for 16–20 h
for Enterobacteriaceae, and for 20–24 h for
Acinetobacter spp.
Susceptibility tests were performed on the
Vitek 2 system using AST-N032 test cards, inocu-
lated according to the manufacturer’s guidelines.
MICs were determined without application of the
expert rule base.
Colistin Etests (AB Biodisk) were performed on
Mueller–Hinton agar plates according to the
manufacturer’s guidelines. Etest strips were
applied when the agar surface was completely
dry, and were incubated at 35C for 18 h. The
MIC was determined at the point where inhibi-
tion of growth intersected the Etest strip. The
highest MIC intersect was recorded if micro-
colonies were present within the zone of inhibi-
tion, or if the ellipse was asymmetrical. For
comparison purposes, Etest MICs were rounded
up to the next highest two-fold dilution. Escheri-
chia coli ATCC 25922 and P. aeruginosa ATCC
27853 were used as quality control organisms
for all testing methods. Quality control findings
were in line with published standards [2].
Essential agreement between agar dilution and
Etest was defined as MICs that were within
±1 log2 dilution of each other. MIC agreement
between agar dilution and Etest was only
evaluated for isolates with an agar dilution MIC
of 0.5–64 mg ⁄L, and between agar dilution and
Vitek 2 for isolates with a Vitek MIC of 1–8 mg ⁄L,
as the MIC ranges for Etest (0.06–1024 mg ⁄L) and
Vitek 2 (1–8 mg ⁄L) differed from that available
for agar dilution. Organisms with a colistin MIC
of ‡4 mg ⁄L were considered to be resistant, and
categorical agreement was calculated using this
breakpoint. The agar dilution result was taken
as the reference method against which results
from the other two methods were compared.
A very major error denoted a false-susceptible
result, and a major error denoted a false-resistant
result.
In total, 54 (31%) Gram-negative isolates were
resistant to colistin, with resistance detected in
Morganella spp. (3 ⁄ 3, 100%), Serratia spp. (9 ⁄ 9,
100%), S. maltophilia (9 ⁄ 9, 100%), Enterobacter spp.
(15 ⁄ 20, 75%), P. aeruginosa (15 ⁄ 47, 32%) and
Klebsiella spp. (3 ⁄ 18, 17%). No resistance was
detected in Acinetobacter spp. and E. coli.
There was categorical agreement between the
Etest and agar dilution for 149 (86.6%) tests.
There were eight (4.7%) very major errors and 15
(8.7%) major errors; 19 (83%) of the errors were
detected when testing P. aeruginosa, two when
testing Enterobacteriaceae, and one error each
when testing Acinetobacter spp. and S. maltophilia
(Table 1). Based on the isolates tested, the Etest
had a sensitivity of 85% and a specificity of 87%
for detecting colistin resistance, with a positive
predictive value of 75%, and a negative predictive
value of 93%. There was categorical agreement
between the Vitek 2 system and agar dilution for
Table 1. Errors in comparison with agar dilution when
testing susceptibility to colistin by Etest and the Vitek 2
system
Organism tested
No.
tested
Etest Vitek
Major error
(% of total)
Very major
error
(% of total)
Major error
(% of total)
Very major
error
(% of total)
Acinetobacter spp. 58 1 (2) 0 0 0
Enterobacteriaceae 58 0 2 (4) 0 15 (26)
Pseudomonas
aeruginosa
47 14 (30) 5 (11) 0 14 (30)
Stenotrophomonas
maltophilia
9 0 1 (11) 0 2 (22)
Total 172 15 (8.7) 8 (4.7) 0 31 (18.0)
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141 (82%) tests. There were 31 very major errors,
but no major errors were detected. The Vitek 2
system failed to detect colistin resistance in some
isolates of P. aeruginosa, Enterobacter spp., Klebsi-
ella spp. and S. maltophilia (Table 1). The Vitek 2
system had a sensitivity of 43% and a specificity
of 100% in detecting colistin resistance, with a
positive predictive value of 100%, and a negative
predictive value of 79%. Essential agreement
between Etest and agar dilution was achieved in
129 (75%) tests (Table 2), and between Vitek 2
and agar dilution in 24 (75%) tests.
The isolates used in this study were nosocomial
and are unlikely to be representative of the general
population. No colistin-resistant Acinetobacter
spp. were detected in the present study, and it
is therefore not possible to draw definitive con-
clusions concerning the efficacy of the Etest or
Vitek 2 systems in detecting colistin resistance in
this genus. Based on the overall results, the
Vitek 2 system was unreliable for detecting colis-
tin resistance in Gram-negative bacilli. The Etest
produced unacceptable error rates for P. aerugi-
nosa and S. maltophilia.
A previous study comparing colistin Etests with
broth microdilution for A. baumannii reported
a very major error rate of 1.7% [5]. Susceptibility
results obtained by colistin Etests may require
confirmation by reference dilution methods. MIC
results for colistin Etests were dependent on the
manufacturer and batch of Mueller–Hinton agar
used, while a 4-h difference in the incubation time
could alter MIC values for P. aeruginosa by
0.5 log2 dilution. In the present study, MICs for
P. aeruginosa were read after incubation for
exactly 18 h. The narrow ellipse of inhibition
produced by Etests requires close scrutiny to
determine MIC endpoints, and high-level resist-
ance in Enterobacter spp. manifests as scanty
single colonies within a clear ellipse of inhibition.
Because of these factors, it would be advisable to
perform concurrent quality control with ATCC
strains.
The best reference method for testing suscep-
tibility to the polymyxins remains to be defined.
Limited data suggest good concordance between
agar dilution and microbroth dilution [6],
although higher MICs have been reported using
agar dilution [7]. Agar dilution and Etest are both
agar-based methods, while Vitek 2 uses inter-
polated data based on growth in liquid media.
There remain many unresolved questions regard-
ing polymyxin susceptibility testing, including
the effect of the sulphate vs. sulphomethyl deriv-
atives, anion content and pH on susceptibility test
results [8]. In addition, there is no consensus
regarding the interpretative breakpoints for
polymyxin susceptibility; e.g., the CLSI specifies
susceptibility breakpoints of <4 mg ⁄L for Acine-
tobacter spp., whereas the guidelines of the British
Society for Antimicrobial Chemotherapy specify
a susceptibility breakpoint of <8 mg ⁄L (http://
www.bsac.org.uk/_db/_documents/version_5_.
pdf).
With increasing use of polymyxins for the
treatment of multiresistant Gram-negative infec-
tions, further and more extensive studies are
needed to clarify susceptibility testing methods
for these compounds.
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ABSTRACT
Between January 2001 and December 2005, 1263
patients suspected of having echinococcosis were
screened serologically by indirect haemagglutina-
tion assay (IHA). IHA-positive patient sera were
then retested by western blot for confirmation and
differentiation between Echinococcus granulosus
and Echinococcus multilocularis infection. Of 43
sera confirmed as Echinococcus-positive, nine
appeared to be specific for alveolar echinococcosis
(AE) caused by E. multilocularis. AE-positive se-
rological results corresponded to the clinical
and ⁄ or imaging findings concerning the patients’
liver cysts. The detected incidence of AE was
0.45 ⁄ 105 inhabitants, which suggests that clini-
cians and health authorities in Slovenia should
give greater attention to AE in the future.
Keywords Alveolar echinococcosis, diagnosis, Echi-
nococcus, indirect haemaglutination assay, Slovenia,
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Human echinococcosis is caused mainly by the
larvae of the tapeworm Echinococcus granulosus,
which cause cystic echinococcosis (CE), and by
the larvae of Echinococcus multilocularis, which can
cause alveolar echinococcosis (AE). E. granulosus
occurs worldwide, but E. multilocularis is found
only in the temperate northern hemisphere. The
main endemic areas of this tapeworm are Alaska,
Canada, central North America, some parts of
central western Europe, western Turkey, Russia,
China, central Asia and northern Japan. At the
adult stage, E. multilocularis is 1.2–3.7 mm in
length and is harboured in the intestine of
definitive hosts, typically foxes, and also domestic
dogs and cats. The tapeworm eggs are excreted
with the faeces. Following accidental ingestion of
these eggs, the larval stage of AE may develop in
many species of small rodents, and sometimes in
humans as intermediate hosts, usually in the liver.
AE is potentially fatal and is chronically progres-
sive as a tumour-like hepatic disease [1–6]. The
aim of the present study was to examine ser-
ologically whether patients in Slovenia suspected
of having echinococcosis had been infected by the
larvae of E. multilocularis.
Between 1 January 2001 and 31 December 2005,
1263 patients suspected of having echinococcosis
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